Of note, other ABL1 fusions that are expressed in Ph-like- and T-cell acute lymphoblastic leukaemias were described to respond to ATP-competitive BCR::ABL1 inhibitors in cells lines and in clinical trials [14]. Here, ABL1 is linked to T-cell acute lymphoblastic leukemia.